Sentence examples for vaccination range from inspiring English sources

Samples were collected from 363 individuals with a mean of 29.6 ± 8.42 months after their last vaccination (range 3 57 months).

Incrementally expanding the vaccination range has the advantage of easing the logistical implementation and the funding process.

However, five out of eight patients showed a more than twofold increase in CD25+ FoxP3+ CD127low CD4+ T cells in one or both time points after vaccination (range 2.4 6.0-fold 2.4 6.0-foldincrease.

After vaccination, the frequency of IFNγ- and/or TNFα-secreting cells increased twofold until day 42 or 84 after vaccination (range 2.8 17.8-fold increase) (Table  2; Supplementary Fig. 3).

In five of eight patients, PADRE-specific CD4+ T cells were detected prior to vaccination (range 0.20 0.40% of CD4+ T cells) that produced either IFNγ or TNFα, but no IL2, IL4, or IL10 production was detectable (Fig.  2c and data not shown for IL4 and IL10).

All of the four patients with congenital asplenia or spherocytosis already had high antibody concentrations before vaccination (range: 1.34 92.97 μg/ml) and did not have an increase afterwards (Table  1), whereas many patients with splenectomy clearly benefited from the vaccination (Table  1), especially those with low antibody concentrations prevaccination (Fig.  1).

The degree of protection obtained after mucosal vaccination ranges from reduction of symptoms to complete inhibition of re-infection.

Institutional requirements for influenza vaccination, ranging from policies that mandate declinations to those terminating unvaccinated healthcare personnel (HCP), are increasingly common in the US.

The rates for seroprotection (HI>40; SRH>25MN2; MN ≥40) after the primary vaccination ranged 72 87%.

The first vaccination induced an HI response in at least one subject in each group of 30 children, but titres remained low: the GMT 21 days after the first vaccination ranged from 4.29 (95% CI: 3.8 4.83) to 8.48 (95% CI: 5.34 13.5) per group.

The nation-wide coverage of rotavirus vaccination ranged from 42% - 56% in 2012 and 73% - 93% in 2013.